ClearNote Health Raises $52M Series D as Cancer Diagnostics Faces a Reality Check

ClearNote Health just raised $52M in Series D financing, pushing total funding beyond $185M and reinforcing investor confidence in clinically grounded cancer diagnostics platforms. The San Diego-based company develops blood-based early cancer detection tests using a proprietary 5hmC epigenomic platform combined with AI. The round was led by founding investor Mattias Westman and an undisclosed global long-only active manager, with participation from Sandy Weill, Stephen Quake, D.Phil. of Stanford University, a large Seattle-based family office, and additional U.S. and international institutional investors. The timing matters because cancer diagnostics remains one of the most heavily watched sectors across healthcare AI and precision medicine, but the market has shifted sharply since the biotech funding boom. Investors no longer reward ambition alone. Clinical validation, reimbursement pathways, operational infrastructure, and physician trust now determine which companies survive long enough to matter. ClearNote Health appears to understand that better than most.

What Happened

ClearNote Health announced a $52M Series D financing round aimed at accelerating commercial expansion, operational scale-up, clinical study execution, and continued development of its Avantect and Virtuoso platforms. Founded in 2016 as Bluestar Genomics before rebranding in 2022, ClearNote Health emerged from research conducted in the Stanford laboratory of Stephen Quake. The company focuses on blood-based early cancer detection for high-mortality cancers including pancreatic cancer and ovarian cancer.

ClearNote Health’s core technology analyzes 5-hydroxymethylcytosine, known as 5hmC, in cell-free DNA collected through a standard blood draw. Unlike mutation-first liquid biopsy approaches that search primarily for genetic alterations, 5hmC analysis focuses on epigenetic changes associated with active disease biology. The company combines those epigenomic signals with AI models designed to identify cancer earlier in clinically meaningful ways, a distinction that carries weight in modern diagnostics markets. Avantect Pancreatic launched commercially in 2023, followed by Avantect Ovarian in 2024, while testing availability now extends across more than 50 countries through international distribution agreements. NHS England selected Avantect Pancreatic for a study involving up to 15,000 patients newly diagnosed with Type 2 diabetes, and the U.S. National Cancer Institute selected ClearNote Health for its Vanguard Multicancer Detection Study evaluating emerging blood-based cancer screening technologies. Biotech loves ambition. Healthcare systems prefer proof.

Why This Matters

Pancreatic cancer remains one of the deadliest forms of cancer largely because diagnosis often occurs after the disease has already progressed significantly. Earlier detection changes treatment options, survival probabilities, and long-term care economics almost immediately, creating enormous pressure inside the diagnostics industry. Blood-based cancer detection has become one of healthcare’s loudest battlegrounds. Decks everywhere. Grand promises everywhere. Then reality walks in wearing steel-toe boots through clinical validation, reimbursement, regulatory scrutiny, distribution logistics, false-positive risk, physician adoption, and operational scale.

That pressure intensified after the biotech correction reshaped venture markets beginning in 2022. Diagnostics startups that once raised capital on broad AI narratives alone suddenly faced a far harsher environment where commercial durability mattered more than presentation quality. ClearNote Health sits in a stronger position than many peers because the company has assembled multiple layers of institutional validation simultaneously. The company operates a CLIA-certified, CAP-accredited, and New York State Department of Health-approved laboratory infrastructure in San Diego, while CMS reimbursement determinations for Avantect Pancreatic and Avantect Ovarian add another layer of operational credibility that many younger diagnostics companies still lack. Markets eventually punish theater. Healthcare infrastructure rewards evidence.

Leadership and Market Positioning

Dave Mullarkey has led ClearNote Health as CEO since 2022, while the company recently expanded its leadership bench with Kevin Keegan joining as President and COO and Jeffrey Venstrom, MD joining as Chief Medical Officer. The additions signal operational scaling priorities rather than pure research expansion, which matters because diagnostics companies eventually reach a difficult transition point where scientific success and commercial success stop behaving like the same sport. One requires discovery. The other requires execution discipline across reimbursement, provider adoption, laboratory operations, and regulatory navigation.

ClearNote Health also maintains scientific leadership through Samuel Levy, PhD as Chief Scientific Officer and Gulfem Guler, PhD leading translational research and biopharma development initiatives. The broader liquid biopsy market remains intensely competitive, with companies including Guardant Health, Grail, Freenome, and Exact Sciences continuing to compete for physician trust, reimbursement positioning, and long-term market share across precision oncology infrastructure. The loudest company rarely wins healthcare. The company producing durable evidence usually does.

Frequently Asked Questions

What is ClearNote Health?

ClearNote Health is a San Diego-based cancer diagnostics company developing blood-based early cancer detection tests using 5hmC epigenomics and AI.

How much funding did ClearNote Health raise?

ClearNote Health raised $52M in Series D financing, bringing total funding to more than $185M.

What is Avantect?

Avantect is ClearNote Health’s early cancer detection platform focused on high-mortality cancers including pancreatic and ovarian cancer.

What does 5hmC mean in cancer diagnostics?

5hmC, or 5-hydroxymethylcytosine, is an epigenetic biomarker used to identify biological changes associated with cancer through blood samples.

Who invested in ClearNote Health’s Series D round?

Investors included Mattias Westman, Sandy Weill, Stephen Quake, D.Phil, an undisclosed institutional manager, and additional institutional investors.

Why does this funding matter for the diagnostics market?

The funding reflects continued investor confidence in clinically validated cancer detection platforms as healthcare markets increasingly prioritize operational credibility and reimbursement readiness.

What cancers is ClearNote Health targeting?

ClearNote Health currently focuses on pancreatic and ovarian cancer detection while also pursuing broader multicancer detection initiatives.

Where is ClearNote Health headquartered?

ClearNote Health is headquartered in San Diego, California.